What Is an STS Test for Syphilis?

An STS, or serologic test for syphilis, is any blood test that detects syphilis infection by looking for antibodies in your blood rather than for the bacterium itself. The term dates back more than a century and encompasses two broad families of tests: non-treponemal tests like the RPR and VDRL, which pick up general immune activity triggered by tissue damage, and treponemal tests like the FTA-ABS and TPPA, which detect antibodies aimed specifically at the syphilis-causing organism, Treponema pallidum. Understanding which type of STS you received, and what the result actually means, matters more than most people realize, because a single positive or negative result rarely tells the full story.

Where the Term Comes From

The first serologic test for syphilis was developed in 1906 by August Paul von Wassermann, Albert Neisser, and Carl Bruck, who adapted a complement fixation technique to detect antibodies in the blood of infected patients.¹ Their original “antigens” were extracts from tissue loaded with syphilis bacteria, but researchers later discovered that the active substance, called cardiolipin, was a lipid found in perfectly normal tissues, including bovine heart muscle. That discovery is why non-treponemal tests today still use cardiolipin as their target molecule. The Wassermann reaction kicked off a century of refinement, leading to faster and simpler blood tests, but the core idea remains the same: if your immune system has produced certain antibodies, the test picks them up.

Non-Treponemal Tests and What They Measure

When clinicians refer to an “STS” in casual shorthand, they often mean a non-treponemal test, most commonly the RPR (Rapid Plasma Reagin) or the VDRL (Venereal Disease Research Laboratory test). These tests detect a class of antibodies called reagin that your body produces when T. pallidum damages cells and releases lipid material. The tests use a suspension of cardiolipin, lecithin, and cholesterol; if reagin antibodies are present in your blood, the mixture clumps together visibly. A lab technician or automated instrument reads that clumping and reports either a positive or negative, along with a titer, which is a number reflecting the concentration of antibodies.

Titers are expressed as ratios like 1:1, 1:4, 1:16, or 1:64. A higher number means more antibody is present. This number becomes important later, because it is how your doctor tracks whether treatment is working. A key advantage of non-treponemal tests is that they are cheap, fast, and widely available. A key disadvantage is that they are not specific to syphilis. Other conditions can trigger the same antibodies, which means a positive RPR or VDRL does not always mean you have syphilis.

Treponemal Tests and Why You Need Both

Treponemal tests look for antibodies directed specifically at T. pallidum proteins. Common examples include the FTA-ABS (fluorescent treponemal antibody absorption test), the TPPA (Treponema pallidum particle agglutination), and newer automated immunoassays used in high-volume laboratories. In a prospective evaluation, the automated LIAISON Treponema Screen, the ARCHITECT Syphilis TP, and the TPPA all achieved 100% sensitivity, with specificity at or above 99.6%.² Those numbers are reassuring, but there is a catch: once you test positive on a treponemal test, you will almost always remain positive for life, even after successful treatment. That means treponemal tests are excellent for confirming whether someone has ever had syphilis but poor at telling you whether the infection is active right now.

This is exactly why syphilis diagnosis usually requires both types of test. A non-treponemal test tells you about current disease activity (the titer rises with active infection and falls after treatment), while a treponemal test confirms that the antibodies are actually syphilis-related and not a false alarm from some other condition.

Traditional Versus Reverse Screening

Laboratories use one of two main approaches to sequence these tests, and the difference can affect whether your infection gets caught. The traditional algorithm starts with a non-treponemal test (like the RPR) and, if positive, follows up with a treponemal test to confirm. The reverse algorithm flips the order: it starts with an automated treponemal test, and if that is positive, follows up with an RPR to assess disease activity.

The reverse algorithm has become increasingly popular in large labs because automated treponemal tests are easier to run in bulk. But the two approaches do not always agree on who has syphilis. In one study at a national referral laboratory, the reverse algorithm found a significantly higher rate of syphilis than the traditional algorithm, and the traditional algorithm missed roughly a third of diagnoses that the reverse algorithm caught.³ On the other hand, in a population with low syphilis rates, the reverse algorithm produced more false-reactive results (six false positives among a thousand patients, compared to zero with traditional screening), though it also identified two patients with possible latent syphilis that the traditional approach missed entirely.⁴

Neither algorithm is perfect, and where you live, who you are, and how common syphilis is in your area all influence which approach your lab likely uses. If you are told you tested positive, it is reasonable to ask which algorithm was used and whether a confirmatory test has been done.

Why a Positive STS Might Not Mean Syphilis

False-positive results on non-treponemal tests are a well-known headache. Because the RPR and VDRL detect antibodies against cardiolipin rather than against the syphilis bacterium itself, any condition that stimulates those antibodies can trip the test. Autoimmune diseases are the biggest culprits. A large retrospective study of nearly 36,000 syphilis tests found that autoimmune diseases and specific autoantibodies are key contributors to biologically false-positive reactions.⁵ Conditions like lupus, rheumatoid arthritis, and antiphospholipid syndrome are common offenders. Cancer and older age also play a role: a ten-year analysis at a teaching hospital found that most biologically false-positive reactions occurred in patients over 60 with a history of malignancy or autoimmune disease.⁶

Pregnancy, recent vaccinations, and certain viral infections can also produce transient false positives. This is why a reactive RPR or VDRL should always be confirmed with a treponemal test before you are diagnosed. If the treponemal test comes back negative, the initial result was almost certainly a false alarm.

Why a Negative STS Might Not Mean You Are Clear

False negatives are less discussed but just as important. The most notorious cause is the prozone phenomenon, a paradox where antibody levels are so high that they actually prevent the test from working. In the standard flocculation reaction, antibodies need to cross-link with antigen particles to form visible clumps. When there is a massive excess of antibody, those clumps fail to form and the test reads as negative.⁷ This is most likely to happen during secondary syphilis, when the immune system is in overdrive and antibody levels peak. It can also occur in people co-infected with HIV.⁸

Labs can get around this by diluting the blood sample and retesting, which brings the antibody concentration down into the range where clumping can occur normally. But if the lab does not suspect the issue and does not dilute, the patient gets a falsely reassuring result. If you have symptoms that look like secondary syphilis (widespread rash, mucous patches, swollen lymph nodes) and your RPR comes back negative, asking about prozone testing is a reasonable step.

There is also the window period. In very early primary syphilis, the body may not have produced detectable antibodies yet. During this window, both non-treponemal and treponemal blood tests can miss the infection entirely.

Using Titers to Track Treatment

Once syphilis is treated, your doctor will watch your RPR or VDRL titer over time. The standard expectation is a fourfold drop in titer (for instance, from 1:32 down to 1:8) within six to twelve months of treatment. That decline signals that the antibiotics worked and the infection is resolving.

Full seroreversion, meaning the non-treponemal test turns completely negative, happens less often than people expect. In one study of patients treated for early syphilis, only about one in ten had completely negative non-treponemal tests at six months, and fewer than one in five had reached that point by twelve months.⁹ Most patients showed a meaningful drop in titer but never reached zero. This persistent low-level positivity is called the “serofast” state, and it does not necessarily mean treatment failed. During pregnancy, the serofast state is commonly encountered and can cause anxiety when prenatal screening turns up a reactive result, even though the infection was treated long ago.¹⁰

Timing matters for the initial blood draw as well. A study of over 700 syphilis cases found that the longer the gap between the first clinic visit and the day treatment actually started, the more likely the titer was to shift significantly, with about a quarter of cases showing a fourfold change within ten to fourteen days of waiting.¹¹ That kind of fluctuation can complicate follow-up if the “baseline” titer was drawn days before treatment began, because a fourfold change might reflect disease progression before treatment rather than treatment response after it.

Testing the Spinal Fluid for Neurosyphilis

When syphilis infects the central nervous system, standard blood tests alone are not enough. Diagnosing neurosyphilis requires a lumbar puncture (spinal tap) to test cerebrospinal fluid. The CSF-VDRL has long been considered the gold standard for this purpose, and it is extremely specific: if the spinal fluid VDRL is positive, neurosyphilis is very likely. The problem is sensitivity. A meta-analysis of CSF testing found that non-treponemal tests on spinal fluid had a pooled sensitivity of about 77%, meaning they miss roughly one in four cases. Treponemal tests on spinal fluid were more sensitive at around 95% but less specific, with more false positives.¹²

Among the non-treponemal spinal fluid tests, the TRUST (toluidine red unheated serum test) performed somewhat better than the VDRL and RPR in terms of sensitivity in the same analysis. Among treponemal options, enzyme immunoassay stood out, achieving about 99% sensitivity and 98% specificity. In practice, many clinicians still rely on the CSF-VDRL and combine it with other indicators like an elevated white blood cell count in the spinal fluid and elevated protein levels, since no single test is perfect for neurosyphilis. After treatment, the spinal fluid RPR titer tends to decline more reliably than the blood RPR titer, with one study finding a fourfold drop in the spinal fluid in the large majority of patients, compared to fewer than half in the blood.¹³

How HIV Co-Infection Complicates the Picture

Syphilis and HIV frequently travel together because they share transmission routes and each infection makes the other easier to acquire. HIV-related immune suppression can distort syphilis test results in unpredictable ways. The prozone effect may be more common. Titers can be unusually high or unusually low. And serological rebound, where a treated patient’s titer spikes back up, becomes harder to interpret. In one reported case, a man with both HIV and secondary syphilis who delayed antiretroviral therapy saw his syphilis titer jump fourfold over just three months, from 1:32 to 1:128, before eventually stabilizing after HIV treatment was started.¹⁴ That kind of serological bounce can look a lot like treatment failure or reinfection, making clinical decisions harder.

Guidelines generally recommend the same STS tests for people with HIV as for anyone else, but closer monitoring is standard. Follow-up titers are often checked more frequently, and the threshold for performing a lumbar puncture to rule out neurosyphilis is lower.

PCR and Direct Detection As Alternatives

Serologic tests detect your immune response to syphilis, not the bacterium itself. That distinction matters most in early primary syphilis, when antibodies may not have appeared yet but the organism is already present in a chancre. PCR (polymerase chain reaction) testing on a swab from a sore can identify T. pallidum DNA directly. A study comparing PCR to traditional dark-field microscopy found moderate agreement between the two methods, with PCR offering an advantage in settings where dark-field microscopy is unavailable.¹⁵

A more recent study found that PCR and IgM immunoblotting each added timely diagnosis in roughly a quarter of early syphilis patients who would otherwise have been missed or diagnosed later by conventional serology alone.¹⁶ PCR is especially useful in suspected reinfection, where treponemal tests are already positive from a previous episode and standard serology alone cannot confirm a new infection. The main drawback is availability and cost: PCR is not offered in every lab, and it requires a swab from an active lesion rather than a simple blood draw.

Point-of-Care Rapid Tests

In resource-limited settings, even a basic RPR may require equipment and trained technicians that are not available at every clinic. Rapid point-of-care tests that combine treponemal and non-treponemal detection on a single finger-prick strip have been developed to fill this gap. Modeling work has suggested that a dual point-of-care test could save costs in high-prevalence areas while substantially reducing overtreatment of patients who might otherwise be treated presumptively because confirmatory testing is unavailable.¹⁷

Real-world accuracy is still catching up to lab-based tests. In a diagnostic accuracy study among people living with HIV, the treponemal component of a dual rapid test achieved about 75% sensitivity and 97% specificity, while the non-treponemal component had higher sensitivity at about 90% but much lower specificity at around 47%.¹⁸ Those numbers highlight that rapid tests are most valuable where the alternative is no testing at all, rather than as replacements for full laboratory workups.

Cross-Reactivity With Related Infections

Treponema pallidum has close relatives that cause different diseases: yaws, bejel (endemic syphilis), and pinta. These organisms are so similar to the syphilis bacterium that current serologic tests cannot tell them apart.¹⁹ In parts of West Africa, Southeast Asia, and the Pacific Islands where yaws remains endemic, a positive treponemal test could reflect a childhood yaws infection rather than sexually transmitted syphilis. Distinguishing between these requires clinical context, travel and exposure history, and sometimes PCR-based methods that target genetic differences between subspecies. For clinicians working in or seeing patients from these regions, a reactive STS is the starting point of a conversation, not the end of one.

Screening in Pregnancy

Syphilis during pregnancy can cause devastating outcomes, including stillbirth, neonatal death, and congenital syphilis in the newborn. The U.S. Preventive Services Task Force recommends early, universal screening for syphilis infection during pregnancy, regardless of whether risk factors are present.²⁰ In many U.S. states, repeat screening in the third trimester and again at delivery is now required by law, reflecting the steep rise in congenital syphilis cases over the past decade.

Interpreting STS results during pregnancy comes with its own wrinkles. Pregnancy itself can trigger low-titer false-positive RPR results, and previously treated women may present in the serofast state described earlier, making it difficult to distinguish old infection from new. Close communication between the obstetric team and an infectious disease specialist can prevent both unnecessary retreatment and dangerous under-treatment.

Laboratory Automation and What It Means for Accuracy

Reading an RPR or VDRL under a microscope involves a degree of human judgment: is that clumping or isn’t it? Automated RPR instruments that standardize the reading process are increasingly common in larger labs, with the potential to reduce turnaround time and minimize interpretation errors.²¹ From a public health standpoint, the shift toward automation also makes the reverse screening algorithm more practical, since automated treponemal immunoassays can process hundreds of samples at once. An economic analysis estimated that reverse screening detected nearly ten percent more syphilis cases than the traditional algorithm, at an incremental cost of about $39 per additional case detected from the public health department’s perspective.²² In a high-prevalence population, that tradeoff is easy to justify.